M arfan syndrome was first described in 1896. It was not originally identified that aortic dilatation/rupture was a threat associated with this syndrome. This leads Reed Pyeritz to suggest that the original description did not present what is called today Marfan syndrome. However, even after the recognition of the aortic risk associated with the syndrome, the nosology continued to evolve leading to different diagnostic criteria. 1 Molecular genetic studies associated FBN1 mutations with the majority of cases, and subsequently they recognized that TGFBR2 mutations could also be responsible for the same combination of clinical features, except severe ectopia lentis leading to surgery.
See Article by Roman et al
It is generally understood that Marfan syndrome is associated with tissue fragility, leading to ectopia lentis (secondary to structurally altered zonules), progressive aortic dilatation (secondary to disorganization of the medial elastic network) which may lead to aortic dissection and rupture, mitral valve prolapse (secondary to elongation of chordae), pneumothorax, striae, protrusia acetabulae, and excessive growth of bones responsible for pectus deformities, arachnodactyly, excessive arm span. The numerous systems affected make the diagnostic difficult, which is responsible for both over-and misdiagnosis, calling for international criteria.
Positive or negative diagnosis is clearly more difficult in mildly affected pediatric patients, and the rule is therefore to propose regular follow-up until adulthood, that is, when it is agreed that significant clinical features should have appeared. Positive or negative diagnosis is also difficult in adult relatives with nonconclusive clinical features and at risk of developing life-threatening vascular complications. However, the larger use and availability of genetic screening, when positive, has considerably facilitated familial screening and early diagnosis of affected or at-risk patients. Early diagnosis is important to adapt lifestyle and propose early β-blocker therapy which remains the mainstay of medical treatment after the disappointment encountered with the losartan clinical trials. 2 Therefore, identifying the timing of the appearance of clinical features is important in this context. This study by Roman et al 3 is thus timely. The authors have evaluated the appearance of clinical features in children versus adults using the quality data from the very large GenTAC population.
The GenTAC Registry was established in 2006 to collect information from eligible patients with genetic conditions predisposing them to thoracic aortic aneurysms to assist physicians and researchers in understanding the link between genes, aortic aneurysms, and heart disease. The GenTAC Registry concluded in 2016. This important US registry made possible many successful research studies that allowed progress in the understanding of genetic TAAD and specifically Marfan syndrome. Notably, studies from this registry focused on chronobiology of aortic dissection which does not differ from aortic dissection in non-Marfan patients, 4 evaluated the risk associated with pregnancy in women with Marfan syndrome, 5 stressing the importance of the descending aorta and the increased risk of aortic dissection in the immediate postpartum period. It also underscored the risk of aortic dissection in patients with Marfan syndrome even after TAA grafting, suggesting that aortic surgery may be a marker for a more severe aortic disease. 6 This registry was also important in stressing the role for standardization in measurement of aortic diameter, because of the variability in measures obtained from different reference centers participating in the registry. 7 GenTAC, although focused on genetically triggered aortic aneurysm/dissection, does not require genetic screening for a patient to be included: in fact, in the article from Roman et al, an FBN1 gene mutation was recognized in only 28% of the population. Interestingly, patients with mutations in genes other than FBN1 were excluded, despite the fact that 20% of patients with a TGFBR2 gene mutation would fulfill systemic score for Marfan syndrome. 8, 9 This overlap in phenotype observed between patients with a TGFBR2 mutation or an FBN1 gene mutation has long been a matter of debate 10 that is now extended to patients with other TAA-associated gene mutations. 11, 12 One limit of the study is therefore the criteria used to define Marfan syndrome in the absence of complete systematic screening of all the patients. The last definition proposed for Marfan syndrome, which was used here, requires the presence of 2 features among (1) aortic dilatation, (2) ectopia lentis, (3) systemic score >7, and (4) a pathogenic mutation in the FBN1 gene. 1 This definition leads to expecting over-representation of 1 cardinal feature in a given population fulfilling criteria despite incomplete evaluation of another feature; indeed, aortic Marfan Syndrome: Always Evolving dilatation is expected to be over-represented in the absence of gene mutation screening. Therefore, one can expect overrepresentation of young patients with aortic dilatation as skeletal features would not have appeared yet and FBN1 mutation had not been sought. A different approach, namely looking at a population defined by the finding of a pathogenic FBN1 mutation logically, would lead to a different result: indeed, aortic dilatation prevalence increases with aging in such a population. 13 However, whether all patients with an FBN1 mutation will 1 day in life fulfill the diagnostic criteria for Marfan syndrome has not been studied, and each study design has its weakness.
Besides, aortic dilatation is a difficult matter: its definition is problematic, and this is reflected by the many different calculations proposed for the z score. The nomograms from Roman et al 14 were the first ones proposed and initially widely used. However, we and others found that this definition lead to overdiagnosis of aortic dilatation in children: the purported dilatations disappeared during follow-up as the children grew. This leads us to propose an alternative calculation of z score for children 15 ; this nomogram has been expanded by others with new values for adults and children, 16 and nomograms based on height only now allow estimation of aortic dilatation in tall and thin patients. 17 Finally, in the last nosology proposed, the z score threshold used for children was 3 (meaning that aortic dilatation is diagnosed only when the z score is >3), whereas it is 2 for adults (meaning a z score >2 defines an aortic dilatation in adults). 1 It is unclear in the article from Roman et al, which was the criterion chosen or the mode of calculation for the z score. In conclusion, the long discussion in the previous paragraphs stresses the difficulty in diagnosing aortic dilatation in a given population.
The article from Roman et al discusses other important issues. It has been a general finding that aortic diseases are more severe in men than women. 8, 13, 18, 19 The reason for this remains unclear and raises the issue of modifier genes or factors. Actually, the variability of the severity of aortic dilatation in patients with Marfan syndrome is important, and not explained only by sex. 9 Numerous genotype/phenotype correlations have been looked for with moderate success, with the exception of the neonatal forms of Marfan syndrome. 20 Faivre et al 21 reported the association of mutations affecting cysteine residues and ectopia lentis, and more recently nonsense mutations were associated with a more severe cardiovascular phenotype.
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Conclusions
Evolution with aging is the rule for the features of Marfan syndrome and is expected as the alteration in fibrillin weakens tissue resistance, accelerating fatigue of this biomaterial 23 : ectopia lentis is present early, the aortic dilatation is difficult to diagnose during childhood, and the various other clinical features, including musculoskeletal anomalies, occur progressively during growth from childhood to adulthood. Much remains unknown in this always evolving disease, despite the significant advances made in the last decades. For this reason, the contribution of all work mining the GenTAC cohort data provides and will provide important contributions to the understanding of Marfan syndrome and other aortic diseases.
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